Potential Updates to FDA’s Protocol Deviations Guidance
In this video interview, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, talks FDA’s latest protocol deviation guidance and potential changes to the draft.
In a recent video interview with Applied Clinical Trials, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, discussed FDA's recent guidance on protocol deviations and its impact on clinical trial management. She highlighted the importance of quality by design (QbD) and critical to quality (CTQ) factors in reducing protocol deviations. Pomerantseva views this guidance as an official acknowledgment of existing practices and an opportunity for improvement.
ACT: How do you think FDA’s protocol deviations (PDs) guidance will affect the industry moving forward into the future?
Pomerantseva: I see it as a great first step in acknowledging the complexity of this process and providing more clarity to the industry, and therefore, I hope that all the industry professionals will take advantage of the opportunity to provide comments. I actually reviewed some comments a couple of days ago. There is not too many, so I would envision that we could collaborate much better on helping ourselves to have a more consistent and more concise document.
I would definitely expect more details in the guidance, and then it's going to evolve over time, but again, I'm a now person, let's see what we can do now, not waiting for another revision since we have the chance. For example, I would expect more guidance on a couple things, and I'm going to be very specific or what I haven't seen there, but I would want to. Serious breaches: at what point should important PDs be assessed for being serious breaches, if it should be assessed, and what role should be involved? Maybe it should reference a dedicated serious breaches guidance, but I haven't seen anything in there. Governance, metrics, and escalation: it is a big topic in ICH E6(R3), but I have not seen anything on this topic in the protocol deviation guidance.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
